tetano
Editor, Senior Moderator
Vaccine. 2015 Jan 5. pii: S0264-410X(14)01716-2. doi: 10.1016/j.vaccine.2014.12.061. [Epub ahead of print]
[h=1]Increasing cellular immunogenicity to peptide-based vaccine candidates using a fluorocarbon antigen delivery system.[/h] Francis JN[SUP]1[/SUP], Thaburet JF[SUP]2[/SUP], Bonnet D[SUP]3[/SUP], Sizer PJ[SUP]2[/SUP], Brown CB[SUP]2[/SUP], Georges B[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Traditionally, synthetic peptide vaccines for infectious diseases and cancer require adjuvants to achieve optimal immunogenicity. Here we describe a novel method of peptide modification using a fluorocarbon chain which can substantially increase peptide-specific cellular immune responses in the absence of adjuvant. We demonstrate that fluorocarbon-modified peptides (fluoropeptides) derived from HIV, influenza and hepatitis C virus can significantly increase interferon gamma ELISpot responses against cytotoxic and T-helper epitopes compared to unmodified peptides or lipopeptides in mice. Increases in both T-helper1 and T-helper2 cytokines are observed. Fluoropeptides show enhanced ability of the antigen to persist at the site of administration and persistence is associated with a prolonged and elevated immune response. Additionally we demonstrate that fluoropeptides have increased proteolytic resistance thereby potentially supporting their increased half-life in vivo. Fluorocarbon-modification of peptides provides a valuable tool for increasing cellular immunogenicity of vaccines for infectious diseases and cancer without requirement for traditional adjuvants.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Delivery system; Fluoropeptide; Immunogenicity; Vaccine
PMID: 25573036 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25573036
[h=1]Increasing cellular immunogenicity to peptide-based vaccine candidates using a fluorocarbon antigen delivery system.[/h] Francis JN[SUP]1[/SUP], Thaburet JF[SUP]2[/SUP], Bonnet D[SUP]3[/SUP], Sizer PJ[SUP]2[/SUP], Brown CB[SUP]2[/SUP], Georges B[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Traditionally, synthetic peptide vaccines for infectious diseases and cancer require adjuvants to achieve optimal immunogenicity. Here we describe a novel method of peptide modification using a fluorocarbon chain which can substantially increase peptide-specific cellular immune responses in the absence of adjuvant. We demonstrate that fluorocarbon-modified peptides (fluoropeptides) derived from HIV, influenza and hepatitis C virus can significantly increase interferon gamma ELISpot responses against cytotoxic and T-helper epitopes compared to unmodified peptides or lipopeptides in mice. Increases in both T-helper1 and T-helper2 cytokines are observed. Fluoropeptides show enhanced ability of the antigen to persist at the site of administration and persistence is associated with a prolonged and elevated immune response. Additionally we demonstrate that fluoropeptides have increased proteolytic resistance thereby potentially supporting their increased half-life in vivo. Fluorocarbon-modification of peptides provides a valuable tool for increasing cellular immunogenicity of vaccines for infectious diseases and cancer without requirement for traditional adjuvants.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Delivery system; Fluoropeptide; Immunogenicity; Vaccine
PMID: 25573036 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25573036